New Weight-Loss drug HS235 begins first human tests
NCT ID NCT06714825
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested HS235, an experimental drug, in 39 overweight or obese but otherwise healthy adults. The main goal was to check safety and how the drug behaves in the body, not to measure weight loss. Participants received either HS235 or a placebo as a shot under the skin. Results will help decide if further studies are warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HS235
- What this could lead to
- If safe and effective, HS235 could become a new option for weight management in people with overweight or obesity.
- What could go wrong
- This is a very early Phase 1 trial with only 39 people. It is designed to check safety and how the drug moves through the body, not whether it works for weight loss. Many drugs fail at this stage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Syneos Clinical Research Unit
Québec, Quebec, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Can a Boron-Based pill tame obesity and blood sugar?
- Citrus flavonoid hesperidin put to the test as a brain booster for overweight adults
- Could dimming lights and early dinners boost insulin sensitivity?
- Extra sleep may boost insulin sensitivity and cut heart risk
- Can changing when and what you eat trick your body into making less fat?